Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device
March 20 2024 - 3:05PM
Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing
and precision medicine, today announced that the U.S. Patent and
Trademark Office has granted a patent that covers the use of
push-button blood collection devices for PCR-based fetal sex
determination.
U.S. Patent No. 11,932,907, titled Fetal Sex Determination Using
Capillary Blood From Upper Arm, provides protection for Myriad’s
SneakPeek Snap® products in the U.S through 2040. The patent
further covers technology for improving the accuracy of a fetal sex
test by reducing contaminating DNA in maternal blood samples.
SneakPeek’s blood collection innovation makes obtaining a blood
sample at home quick and easy. Consumers place the Snap device on
their arm, press the button, and the sample is collected in one to
four minutes. Moreover, clinical studies have shown that the Snap
device significantly reduces the risk of external male DNA
contamination in maternal blood samples, ensuring high accuracy in
fetal sex testing.
“We view this patent grant as recognition of our innovative
approach to fetal sex testing using PCR-based techniques with any
push-button blood collection device,” stated Dale Muzzey, PhD,
Chief Scientific Officer at Myriad Genetics. “This patent grant
promotes SneakPeek Snap exclusivity in the US market through at
least 2040 and provides an opportunity for licensing agreements
with leading push-button blood collection device suppliers,
positioning us as a strategic partner.”
About Myriad Genetics Myriad Genetics is a
leading genetic testing and precision medicine company dedicated to
advancing health and well-being for all. Myriad develops and offers
genetic tests that help assess the risk of developing disease or
disease progression and guide treatment decisions across medical
specialties where genetic insights can significantly improve
patient care and lower healthcare costs. For more information,
visit www.myriad.com.
Safe Harbor Statement This press release
contains “forward-looking statements” within the meaning of the
Private Securities Litigation Reform Act of 1995, including that
the company expects the SneakPeek Snap patent will provide patent
protection for the company’s SneakPeek Snap products in the U.S.
through 2040 and this patent provides an opportunity for licensing
agreements with leading push-button blood collection device
suppliers. These “forward-looking statements” are management’s
expectations of future events as of the date hereof and are subject
to known and unknown risks and uncertainties that could cause
actual results, conditions, and events to differ materially and
adversely from those anticipated. Such factors include those risks
described in the company’s filings with the U.S. Securities and
Exchange Commission, including the company’s Annual Report on Form
10-K filed on February 28, 2024, as well as any updates to those
risk factors filed from time to time in the company’s Quarterly
Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not
under any obligation, and it expressly disclaims any obligation, to
update or alter any forward-looking statements, whether as a result
of new information, future events or otherwise except as required
by law.
Investor ContactMatt Scalo(801)
584-3532IR@myriad.com
Media ContactGlenn Farrell(385)
318-3718PR@myriad.com
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Apr 2024 to May 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From May 2023 to May 2024